Glypressin (Terlipressin Acetate)

Glypressin is indicated for the management of specific complications associated with advanced liver disease and portal hypertension.

• Control of acute bleeding from esophageal varices in patients with cirrhosis.
• Adjunctive therapy for hepatorenal syndrome to improve renal perfusion.
• Temporary reduction of portal venous pressure during endoscopic procedures.
• Supportive treatment in patients undergoing liver transplantation where portal pressure reduction is required.
• Management of refractory hypotension secondary to severe vasodilation in hepatic failure.

The pharmacologic activity of Glypressin may be associated with a range of adverse effects, which are generally categorized by frequency and clinical significance.

Common

• Headache, dizziness, or flushing caused by transient vasoconstriction, usually mild and self‑limiting.
• Nausea, abdominal discomfort, or mild diarrhea, often occurring shortly after infusion.
• Transient increase in blood pressure or heart rate, typically returning to baseline without intervention.

Serious

• Severe hypertension or hypertensive crisis, potentially requiring immediate medical intervention.
• Cardiac arrhythmias, including episodes of tachycardia or bradycardia, which may compromise cardiac output.
• Ischemic events such as myocardial infarction or peripheral limb ischemia, presenting with chest pain or limb discoloration.
• Acute renal failure or worsening of existing renal impairment, manifested by reduced urine output and rising serum creatinine.
• Gastrointestinal ischemia leading to ulceration or perforation, which may cause severe abdominal pain and bleeding.

When prescribing Glypressin, clinicians should evaluate patient-specific factors and monitor for conditions that may increase the risk of adverse outcomes.

• Assess cardiovascular status, especially in patients with uncontrolled hypertension or known coronary artery disease.
• Evaluate renal function before initiation and monitor serum creatinine during therapy.
• Use caution in patients with a history of peripheral vascular disease or ischemic limb conditions.
• Avoid use in individuals with active gastrointestinal bleeding unrelated to varices, as vasoconstriction may worsen ischemia.
• Consider the potential for fluid overload; monitor fluid balance and signs of pulmonary edema.
• Review pregnancy and lactation status, as safety data are limited.

Glypressin may interact with other medications that affect vascular tone, cardiac function, or renal handling; awareness of these interactions helps minimize risk.

Avoid

• Concomitant use with other vasopressors or potent vasoconstrictors (e.g., norepinephrine, phenylephrine) can cause excessive hypertension.
• Co‑administration with phosphodiesterase‑5 inhibitors (e.g., sildenafil) may increase the risk of severe hypotension after vasoconstriction reversal.
• Avoid drugs that prolong the QT interval due to additive cardiac effects.

Use with caution

• Beta‑blockers may blunt the desired hemodynamic response; dose adjustments may be required.
• Loop diuretics can exacerbate renal hypoperfusion; monitor renal function closely.
• Anticoagulants or antiplatelet agents may raise bleeding risk if portal pressure reduction is inadequate; monitor closely.